Exciting post ASCO session next week (june 11) at the IFODS congress in Paris (not to be missed) .... ASCO IFODS

Post-ASCO meeting (June 17) with Gustave's experts Gustave Roussy always a must to better digest all the latest oncology news (and the thoracic part with my super colleagues Benjamin Besse and Dr P.Lavaud...).

A great lung day on Wednesday at the IFODS meeting in Paris! Be there...IFODS #lungcancer ASCO

Let's go for the 1st day of the IFODS meeting (nice place in La Défense 🇫🇷) IFODS

Great review of the latest advances in small cells lung cancer by Laurent Greillier ...impressive recent advances in this disease! IFODS

Excellent radiotherapy/systematic treatment pairing with Drs A.Levy and E.Pons-Tostivint for the latest in localized SCLC treatment .... it's progressing too ! IFODS

A great day for our French 🇫🇷 IFCT lung intergroup ! #lungcancer

Superb presentations and discussion this morning of our EGFRmut patients with our Brazilian colleagues here at the Hospital Albert Einstein Center (Sao-Paulo) Einstein Hospital Israelita. A pleasure to be present with Mihaela Aldea Thanks for the invitation! Gustave Roussy

A wonderful day of presentations and discussions on thoracic oncology at Einstein Hospital Israelita with Mihaela Aldea Gustave Roussy Jose Fernando Moura, PhD Thank you Gustavo Schvartsman for the invitation and the impressive organization of this meeting. Very impressive modern center, superb working tool !

📰 Le professeur Benjamin Besse élu à la présidence de l’organisation européenne pour la recherche et le traitement du cancer, l’EORTC. Lire le communiqué de presse ➡ gustaveroussy.fr/fr/le-professe…

Departure of a GIANT of genito-urinary oncology from Gustave Roussy, Prof. Karim Fizazi... A page is turned for Urology Committee, and the next one will be a challenge to write, but many young talents are there and ready to take over. All the best for Karim's future career ...

Departure of a Giant of Genito-urinary Oncology from Gustave Roussy - David Planchard d.planchard oncodaily.com/blog/david-pla… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

What great news for our EGFRm NSCLC patients, with a survival benefit that confirms the FLAURA2 regimen (Osi + ChemoT) as a new standard of care 1st-line ! We look forward to seeing the final OS data... #EGFR #lungcancer

🔥BREAKING🆙 Positive OS‼️ ✅FLAURA2: Osimertinib + Chemo vs Osimertinib 🎯"Statistically significant and clinically meaningful improvement in the key secondary endpoint of OS" 🗣️AstraZeneca OncoAlert LARVOL #EGFR EGFR Resisters astrazeneca.com/media-centre/p…

Great news!

FLAURA2 Regimen as a New Standart of Care for EGFRm NSCLC - d.planchard oncodaily.com/science/flaura… #NSCLC #EGFRm #LungCancer #LCSM #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

It is always a great success and a pleasure to be able to speak at ESMO Academy to such a wonderful audience with my lung colleagues Jarushka Naidoo Raffaele Califano ESMO - Eur. Oncology

Inspired and grateful to be at #ESMOAcademy2025 in Prague, learning from the lectures of Dr. Planchard & Dr. Califano and fueling my motivation!! 🚀💡 #ESMO #Oncology d.planchard

With targeted therapies and immunotherapy, the progress in treating early-stage NSCLC over the past few years has been impressive, with more and more patients being cured. The remaining goals are prevention and better screening! ESMO - Eur. Oncology #esmoacademy2025

Thrilled to have a fantastic lung team at #ESMOAcademy25 ! Best of luck to our young oncologists taking the ESMO exams ESMO - Eur. Oncology . we hope this provides valuable preparation for your success ! Raffaele Califano Jarushka Naidoo